Dance Biopharm has announced the appointment of Phillips-Medisize President and CEO Matt Jennings to its board of directors. Phillips-Medisize is developing a connected version of Dance’s insulin soft mist inhaler device.
Jennings joined Phillips-Medisize as Chairman, CEO and President in 2011; his prior experience includes 5 years as President of Teleflex and 2 years as President and CEO of Bioenterprise Corporation.
Dance Biopharm CEO Anne Whitaker commented, “We are delighted to have Matt join the company’s board of directors, as he brings a wealth of financial, operations and leadership experience from his distinguished career in the medical device and connected health industry.”
Jennings said, “Emerging companies play an ever more important role in creating medical product breakthroughs. Dance’s founders and their seasoned management team have built a unique advanced insulin delivery platform. I’m excited to have the opportunity to work closely with the Dance team to help bring the promise of this transformative product to patients in need across multiple markets.”
Read the Dance Biopharm press release.
